Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines

Related articles

1. The impact of vaccine products, schedules and geographic regions on immunogenicity of pneumococcal vaccines in children under 2 years old: a systematic review and meta-analysis

   This article has 9 authors:

   1. Xinghui Chen
   2. Sarah Tavlian
   3. Kylie S. Carville
   4. Nefel Tellioglu
   5. Violeta Spirkoska
   6. Natalie Carvalho
   7. David J. Price
   8. Patricia T. Campbell
   9. Jodie McVernon

2. Streptococcus pneumoniae vaccine serotype persistence following 13-valent pneumococcal conjugate vaccine introduction in Mongolia: investigating changes in epidemiology, immunology and virulence

   This article has 20 authors:

   1. Paige Skoko
   2. Sam Manna
   3. Laura K. Boelsen
   4. Jason Hinds
   5. Stephanie W. Lo
   6. Casey L. Pell
   7. Belinda D. Ortika
   8. Rachel A. Higgins
   9. Vicki Bennett-Wood
   10. Hanwen Hou
   11. Odgerel Tundev
   12. Eileen M. Dunne
   13. Cattram D. Nguyen
   14. Fiona M. Russell
   15. E. Kim Mulholland
   16. Tuya Mungun
   17. Paul V. Licciardi
   18. Claire von Mollendorf
   19. Stephen D. Bentley
   20. Catherine Satzke

3. Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for SARS-CoV-2 vaccines in 2024 in Austria

   This article has 4 authors:

   1. Uwe Riedmann
   2. Martin Sprenger
   3. John PA Ioannidis
   4. Stefan Pilz